Chenodeoxycholic Acid

Chenodeoxycholic acid (CDCA) is a primary bile acid synthesized in the liver from cholesterol. It is the most abundant bile acid in human bile and plays a critical role in lipid digestion and absorption. This product is supplied as a white to off-white crystalline powder with ≥98% purity (HPLC), specifically graded for pharmaceutical and research applications.

CDCA is used as an active pharmaceutical ingredient (API) in the treatment of gallstones (cholelithiasis) and is also a key intermediate in the synthesis of other bile acids like ursodeoxycholic acid (UDCA). Its amphipathic nature makes it valuable in formulation science, particularly for enhancing drug solubility and bioavailability.

Sinónimos: Chenodeoxycholic acid, CDCA, 3α,7α-Dihydroxy-5β-cholanic acid, 5β-Cholanic acid-3α,7α-diol, Chenodiol, Chenix, 474-25-9

Aplicaciones

• API for gallstone dissolution therapy (pharmaceutical formulations)
• Starting material for semi-synthetic bile acid derivatives (e.g., UDCA)
• Research reagent in lipid metabolism and bile acid signaling studies
• Excipient or solubilizer in drug delivery systems

Calidad y documentación

Every batch is tested for assay (HPLC ≥98%), loss on drying (≤1.0%), heavy metals (≤10 ppm), and residual solvents. Full COA, MSDS, and TDS are available on request. Stability data can be provided for qualification purposes.

Embalaje y suministros

Envases estándar: 1 kg, 5 kg, 25 kg; también disponibles a granel y en envases a medida. Los artículos en stock se envían en un plazo de 3 a 5 días; cantidad mínima de pedido: 1 kg. Para consultar precios, solicitar muestras y realizar pedidos a granel, ponte en contacto con nuestro equipo de ventas.

Solicitud de presupuesto

• Nuestra dirección: Calle Main, 280, Xi'an, Shaanxi, China
• LyvBio S.L. — Correo electrónico: info@lyvbio.com